endpts.com·Jun 12, 2026
Enliven Therapeutics has priced a $400 million offering, while Jazz Pharmaceuticals' drug Zepzelca has failed a confirmatory study.
The most valuable insight for a professional in healthtech and biotech from this content is that Enliven Therapeutics has priced a $400 million offering, a significant capital raise that could signal investment opportunities or strategic developments in the biotech sector. This offering is noteworthy for those tracking biotech investments and financial movements.